Mode
Text Size
Log in / Sign up

Narrative review links licorice intake to hypokalemia and hypertension in Japanese Kampo patients

Narrative review links licorice intake to hypokalemia and hypertension in Japanese Kampo patients
Photo by Brett Jordan / Unsplash
Key Takeaway
Consider a precision medicine approach for licorice risk assessment in Kampo patients.

This narrative review addresses the clinical implications of licorice intake, specifically focusing on glycyrrhizin, glycyrrhetinic acid, and 3-epi-18β-glycyrrhetinic acid within the context of Japanese traditional Kampo medicine. The publication type is explicitly a narrative review, and no specific sample size or study setting is reported in the source material. The scope covers the potential risks associated with these herbal compounds as used in this specific medical tradition.

The primary synthesized finding indicates that hypokalemia and hypertension are adverse events associated with licorice intake. The review does not report serious adverse events, discontinuations, or specific tolerability data. Consequently, the authors do not provide pooled effect sizes or quantitative risk estimates from primary trials.

The authors suggest that practice relevance lies in adopting a precision medicine approach for risk assessment. This strategy integrates formulation characteristics, host intestinal microbiota function, and physiological reserve to better manage potential risks. The review notes that limitations regarding causality and certainty are not reported in the source text.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Pseudohyperaldosteronism induced by the root of Glycyrrhiza uralensis Fisch. and Glycyrrhiza glabra L (licorice) is a frequent adverse effect of Japanese traditional Kampo medicines, characterized by hypokalemia and hypertension due to the inhibition of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). While daily licorice dosage is a primary risk factor, it often fails to explain inter-individual variability, where some patients develop pseudohyperaldosteronism at low doses while others tolerate high doses. This updated narrative review redefines clinical risk factors based on recent pharmacokinetic discoveries, specifically the identification of 3-epi-18β-glycyrrhetinic acid (3-epi-GA) and the role of intestinal microbiota. We reviewed recent pharmacological and pharmacokinetic evidence regarding the absorption, distribution, metabolism, and excretion of glycyrrhizin and its metabolites. We discuss the pharmaceutical factors altering the absorption of glycyrrhizin, one of the constituents of licorice, such as pH-dependent solubility in Schisandra-containing formulations and enzymatic competition by baicalin in Scutellaria-containing formulations. Importantly, we highlight the “epimerization phenotype,” where specific intestinal microbiota convert glycyrrhizin into 3-epi-GA. Unlike typical GA, 3-epi-GA is resistant to hepatic sulfation by sulfotransferase (SULT) 2A1, leading to prolonged accumulation. Furthermore, hypoalbuminemia increases free metabolite levels, potentially facilitating direct luminal access to renal tubules via glomerular filtration. Combined with the age-related decline in 11β-HSD2 activity and renal excretion via organic anion transporters, these factors create a high-risk metabolic profile. We propose a precision medicine approach for risk assessment that integrates formulation characteristics, host intestinal microbiota function, and physiological reserve, moving beyond simple dosage counting to prevent this iatrogenic condition.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.